Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial (2018)

Peer-Reviewed Study · Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, ter Kuile FO · June 2018

Smit MR et al., 2018-06: Randomized placebo-controlled trial in 141 Kenyan adults with uncomplicated malaria showing that three-day high-dose ivermectin (300 or 600 micrograms/kg/day) added to dihydroartemisinin-piperaquine made their blood lethal to Anopheles mosquitoes for at least 28 days.

Compared with placebo, ivermectin was associated with higher 14 day post-feeding mosquito mortality when fed on blood taken 7 days post treatment (ivermectin 600 μg/kg per day risk ratio [RR] 2·26, 95% CI 1·93-2·65, p<0·0001

Smit MR et al., 2018-06: Randomized placebo-controlled trial in 141 Kenyan adults with uncomplicated malaria showing that three-day high-dose ivermectin (300 or 600 micrograms/kg/day) added to dihydroartemisinin-piperaquine made their blood lethal to Anopheles mosquitoes for at least 28 days. Randomized, double-blind, placebo-controlled superiority trial, N=141 (47 at 600 micrograms/kg/day, 48 at 300, 46 placebo), Kisumu, Kenya; 3 days of ivermectin co-administered with 3 days of dihydroartemisinin-piperaquine; mosquito feeding assays on days 0-28. Comparator: placebo plus DP. Mosquito mortality remained raised at 28 days (RR 1.23 at 600, 1.21 at 300). Funder not carried in the PubMed record, so none is asserted; no conflict statement is indexed either. NCT02511353. Lead is correctly named IVERMAL; the trial measured mosquitocidal efficacy, not malaria incidence. Also filed as IVF-08 (claims C2). Study type: randomized trial.